Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer

2 november 2026 uppdaterad av: dogukan kurc, Istanbul Medipol University Hospital

Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer: A Randomized Controlled Trial

This single-center, parallel-group randomized trial evaluated whether adding an 8-week physiotherapist-supervised pulmonary rehabilitation program to a home program improved functional exercise capacity, pulmonary function, and lung cancer symptoms in adults with stage IIIB/IV small cell lung cancer receiving chemotherapy. Thirty participants were randomized 1:1 to 9 scheduled face-to-face rehabilitation contacts plus twice-daily home exercise and comfortable-pace walking for 20 minutes per day, or to a home program of breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day without face-to-face rehabilitation. Outcomes were assessed at baseline and after 8 weeks. The principal functional outcome for this report was change in 6-minute walk distance; spirometry and the 9-domain Lung Cancer Symptom Scale were exploratory outcomes.

Studieöversikt

Detaljerad beskrivning

BACKGROUND: Patients with stage IIIB/IV small cell lung cancer receiving chemotherapy can experience deterioration in pulmonary function, exercise capacity, symptoms, and quality of life. Evidence for pulmonary rehabilitation during active chemotherapy remains limited.

STUDY DESIGN: Single-center, parallel-group, open-label randomized controlled trial conducted from November 2018 through May 2019.

SETTING: Oncology Department, Yeditepe University Hospital, Istanbul, Turkey.

ETHICS AND REGISTRATION: The Haliç University Ethics Committee approved the study (No. 109; October 30, 2018), and all participants provided written informed consent before enrollment. The trial was retrospectively registered on April 15, 2026.

PARTICIPANTS: Adults aged 18 years or older with stage IIIB/IV small cell lung cancer, Eastern Cooperative Oncology Group performance status 0-2, active chemotherapy, and no more than 3 completed chemotherapy cycles at enrollment. Participants had to understand the intervention instructions and provide written informed consent. Patients with stage I/II disease or a complication contraindicating pulmonary rehabilitation were excluded.

INTERVENTION GROUP: Nine scheduled face-to-face, physiotherapist-supervised contacts across 8 weeks were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The home program was prescribed twice daily, with comfortable-pace walking for 20 minutes per day.

CONTROL GROUP: An 8-week home program of diaphragmatic and thoracic breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day. The control program did not include face-to-face pulmonary rehabilitation, resistance training, postural drainage or percussion, or active-cycle breathing.

OUTCOMES: Change in 6-minute walk distance from baseline to 8 weeks was designated the principal functional outcome for this report. Exploratory outcomes were forced vital capacity, forced expiratory volume in 1 second, FEV1/FVC, peak expiratory flow, forced expiratory flow at 25%-75% of forced vital capacity, and the 9-domain Lung Cancer Symptom Scale, assessed at baseline and after 8 weeks. No prospectively documented primary-secondary outcome hierarchy was located in the available source records.

Studietyp

Interventionell

Inskrivning (Faktisk)

30

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Istanbul, Turkiet (Türkiye)
        • Yeditepe University Hospital, Oncology Department

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Histologically confirmed small cell lung cancer, Stage IIIB or Stage IV
  • Age 18 years or older
  • Receiving active chemotherapy with no more than 3 completed chemotherapy cycles at enrollment
  • Eastern Cooperative Oncology Group Performance Status 0, 1, or 2
  • Able to understand the intervention instructions
  • Written informed consent provided

Exclusion Criteria:

  • Stage I or Stage II small cell lung cancer
  • Any complication contraindicating pulmonary rehabilitation, including a pathological fracture, open wound, unstable cardiac disease, or active uncontrolled infection
  • Inability or refusal to provide written informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Supervised Pulmonary Rehabilitation Plus Home Program

Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day.

Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day.

Aktiv komparator: Home Breathing, Coughing, and Walking Program

Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided.

Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in 6-Minute Walk Test Distance
Tidsram: Baseline and Week 8

Functional exercise capacity measured as the distance walked in a 30-meter indoor corridor. Change is calculated as the Week 8 value minus the baseline value and is reported in meters.

Baseline and Week 8

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in Peak Expiratory Flow
Tidsram: Baseline and Week 8

Peak expiratory flow measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second.

Baseline and Week 8
Change in FEV1/FVC Ratio
Tidsram: Baseline and Week 8

FEV1/FVC ratio measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in percentage points.

Baseline and Week 8
Change in Lung Cancer Symptom Scale Domain Scores
Tidsram: Baseline and Week 8

Nine Lung Cancer Symptom Scale visual analog domains were assessed: appetite, fatigue, cough, dyspnea, hemoptysis, pain, overall lung symptom burden, activities of daily living, and overall quality of life. Scores were recorded on 100-mm visual analog scales and reported on a 0-10 cm scale; lower scores indicate better status. Change is calculated as Week 8 minus baseline, so negative values indicate improvement.

Baseline and Week 8
Change in Forced Expiratory Volume in 1 Second
Tidsram: Baseline and Week 8

Forced expiratory volume in 1 second measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters.

Baseline and Week 8
Change in Forced Vital Capacity
Tidsram: Baseline and Week 8

Forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters.

Baseline and Week 8
Change in Forced Expiratory Flow at 25%-75% of Forced Vital Capacity
Tidsram: Baseline and Week 8

Forced expiratory flow at 25%-75% of forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second.

Baseline and Week 8

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 november 2018

Primärt slutförande (Faktisk)

30 maj 2019

Avslutad studie (Faktisk)

30 maj 2019

Studieregistreringsdatum

Först inskickad

8 april 2026

Först inskickad som uppfyllde QC-kriterierna

8 april 2026

Första postat (Faktisk)

15 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 november 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

IPD-planbeskrivning

A de-identified analytic dataset, data dictionary, and reproducible statistical code may be made available by the corresponding author on reasonable request, subject to ethics, institutional, and consent constraints.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera